Veru Inc (NASDAQ:VERU) — Market Cap & Net Worth
Market Cap & Net Worth: Veru Inc (VERU)
Veru Inc (NASDAQ:VERU) has a market capitalization of $36.76 Million ($36.76 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23126 globally and #5058 in its home market, demonstrating a -3.63% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Veru Inc's stock price $2.39 by its total outstanding shares 16050320 (16.05 Million). Also see VERU asset base for a full breakdown of the balance sheet.
Veru Inc Market Cap History: 2015 to 2026
Veru Inc's market capitalization history from 2015 to 2026. Data shows growth from $23.27 Million to $38.36 Million (1.88% CAGR). Also see VERU cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Veru Inc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2183 of 3165 |
Weight: Veru Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Veru Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Veru Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Veru Inc (VERU) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.62x
Veru Inc's market cap is 0.62 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $14.61 Million | $22.13 Million | $344.73K | 0.66x | 42.37x |
| 2017 | $18.30 Million | $13.66 Million | -$6.61 Million | 1.34x | N/A |
| 2018 | $22.47 Million | $15.86 Million | -$23.94 Million | 1.42x | N/A |
| 2019 | $53.77 Million | $31.80 Million | -$12.02 Million | 1.69x | N/A |
| 2020 | $138.84 Million | $42.59 Million | -$18.97 Million | 3.26x | N/A |
| 2021 | $94.54 Million | $61.26 Million | $7.39 Million | 1.54x | 12.78x |
| 2022 | $84.75 Million | $39.35 Million | -$83.78 Million | 2.15x | N/A |
| 2023 | $11.56 Million | $16.30 Million | -$93.15 Million | 0.71x | N/A |
| 2024 | $10.44 Million | $16.89 Million | -$37.80 Million | 0.62x | N/A |
Competitor Companies of VERU by Market Capitalization
Companies near Veru Inc in the global market cap rankings as of September 18, 2026. Review tangible net worth ratio of Veru Inc to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Veru Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Veru Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Veru Inc's market cap moved from $23.27 Million to $ 38.36 Million, with a yearly change of 1.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $38.36 Million | +11.68% |
| 2025 | $34.35 Million | +228.98% |
| 2024 | $10.44 Million | -9.65% |
| 2023 | $11.56 Million | -86.36% |
| 2022 | $84.75 Million | -10.36% |
| 2021 | $94.54 Million | -31.91% |
| 2020 | $138.84 Million | +158.21% |
| 2019 | $53.77 Million | +139.29% |
| 2018 | $22.47 Million | +22.81% |
| 2017 | $18.30 Million | +25.27% |
| 2016 | $14.61 Million | -37.24% |
| 2015 | $23.27 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Veru Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $36.76 Million USD |
| MoneyControl | $36.76 Million USD |
| MarketWatch | $36.76 Million USD |
| marketcap.company | $36.76 Million USD |
| Reuters | $36.76 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Veru Inc
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosa… Read more